Autolus Therapeutics (NASDAQ:AUTL) Earns “Buy” Rating from Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $10.00 price target on the stock.

A number of other brokerages also recently issued reports on AUTL. Truist Financial lowered their price target on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company decreased their target price on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Price Performance

AUTL opened at $1.36 on Thursday. The stock has a market cap of $361.89 million, a P/E ratio of -1.12 and a beta of 2.06. The firm has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.62. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.37.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million. Equities analysts expect that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. lifted its position in shares of Autolus Therapeutics by 48.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 386,001 shares of the company’s stock valued at $598,000 after acquiring an additional 126,021 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after purchasing an additional 1,125,454 shares in the last quarter. TFG Asset Management GP Ltd boosted its stake in Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock worth $19,388,000 after purchasing an additional 250,000 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Autolus Therapeutics by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company’s stock worth $783,000 after purchasing an additional 15,400 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Autolus Therapeutics by 23.8% during the fourth quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock worth $2,131,000 after buying an additional 174,485 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.